Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 582 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06280924Recruiting
Exercise before or after stem cell transplant for multiple myeloma
This study tests whether a 10-week exercise program (prehab) before or after a stem cell transplant can help people with multiple myeloma feel stronger and recover better. You can join whether you are getting a transplant or not, as long as you live in Alberta and have internet access.
Edmonton, AlbertaAges 18 years+ - NCT06296121RecruitingPhase 3
BCD-264 vs Darzalex for relapsed multiple myeloma
This trial tests a new drug, BCD-264, compared to Darzalex (daratumumab) alone for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if BCD-264 works better than Darzalex in controlling the cancer.
ChelyabinskAges 18 years+ - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Birmingham, AlabamaAges 18 years+ - NCT07454187RecruitingPhase 1/Phase 2
SG2918 for relapsed or refractory multiple myeloma
This trial tests a new drug called SG2918 for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and possibly effective.
Zhengzhou, HenanAges 18–80 - NCT06365060Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
This study is screening people with smoldering multiple myeloma or a monoclonal gammopathy to see if they might have an early form of AL amyloidosis, a condition where abnormal proteins build up in organs. If you meet the criteria, you will be tested to find out if you have amyloidosis, which could help catch it early.
Birmingham, AlabamaAges 40 years+ - NCT06385652RecruitingEarly Phase 1
PET Imaging of Multiple Myeloma with 68Ga-NB381
This study uses a special PET scan to look for multiple myeloma in your body. It may help doctors see where the disease is and how active it is.
Beijing, Beijing MunicipalityAges 18–90 - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06409702RecruitingPhase 4
Treating high-risk multiple myeloma with MRD testing
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
Suzhou, JiangsuAges 18 years+ - NCT06421675RecruitingPhase 2
Elranatamab for multiple myeloma that has come back
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
Vancouver, British ColumbiaAges 18 years+ - NCT06429150RecruitingPhase 1/Phase 2
CAR-T therapy for multiple myeloma or plasmacytoma
This trial tests a new type of immunotherapy called CAR-T cells given as part of an early treatment plan for multiple myeloma or plasmacytoma. The goal is to see if this approach can help achieve a deep remission, especially after a stem cell transplant.
Shenzhen, GuangdongAges 18–80 - NCT06435910RecruitingPhase 1
Dendritic cell vaccine for multiple myeloma in remission
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help keep multiple myeloma from coming back. It's for people whose cancer is in very good remission after other treatments.
Shenzhen, GuangdongAges 18–80 - NCT06463717Recruiting
Stem cell transplant timing for multiple myeloma with no cancer cells left
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hangzhou, ZhejiangAges 18–70 - NCT06474182Recruiting
Apixaban for blood clots in myeloma patients
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
Saint-EtienneAges 18 years+ - NCT06484777RecruitingPhase 1
Study of SHR-9539 for multiple myeloma
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
Chengdu, SichuanAges 18 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT06497738Recruiting
Comparing two drug combos for elderly myeloma
This trial compares two different drug combinations (DRd and VRd-lite) for older adults (65+) who are newly diagnosed with multiple myeloma. The goal is to see which combination works better and is easier to tolerate.
Changzhou, JiangsuAges 65 years+ - NCT06505369RecruitingPhase 2
Immune therapy for newly diagnosed multiple myeloma before stem cell transplant
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
CopenhagenAges 18–70 - NCT06508983RecruitingPhase 3
SG301 for multiple myeloma returning after treatment
This trial tests a new drug called SG301 added to standard treatments (pomalidomide and dexamethasone) for people with multiple myeloma that came back or got worse after prior therapy. It may help if you have tried lenalidomide and a proteasome inhibitor but your cancer is still active.
Beijing, Beijing MunicipalityAges 18–75 - NCT06514508RecruitingPhase 3
Stem cell collection with motixafortide and G-CSF for multiple myeloma
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
Beijing, Beijing MunicipalityAges 18–78 - NCT06515249Recruiting
Integrative therapies for multiple myeloma
This trial offers integrative therapies like acupuncture and reflexology to people with multiple myeloma. It aims to see if these treatments can help improve well-being and manage symptoms.
HaifaAges 18 years+ - NCT06517017RecruitingPhase 2
Gentle combination therapy for frail myeloma patients
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
Salt Lake City, UtahAges 18 years+ - NCT06520176RecruitingPhase 3
Comparing two stem cell collection methods for multiple myeloma
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
Dongyang, ZhejiangAges 18–75 - NCT06523699RecruitingPhase 1
Testing interleukin-7 after stem cell transplant for myeloma
This study tests whether a drug called interleukin-7 (CYT107) can help your immune system recover faster and clear myeloma cells better after a stem cell transplant. You would receive CYT107 injections after your transplant, and the study will check if this improves your long-term outcome.
St Louis, MissouriAges 18 years+ - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 582 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.